A5008754625- Breast Cancer Treatment Studies
- Global Cancer Incidence and Screening
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- BRCA gene mutations in cancer
- Breast Lesions and Carcinomas
- Economic and Financial Impacts of Cancer
- Cancer-related molecular mechanisms research
- RNA modifications and cancer
- Neuroblastoma Research and Treatments
- Antifungal resistance and susceptibility
- Cancer Treatment and Pharmacology
- Biomedical Ethics and Regulation
- Cancer Risks and Factors
- Empathy and Medical Education
- Public Health in Brazil
- PARP inhibition in cancer therapy
- Brain Metastases and Treatment
- Gastric Cancer Management and Outcomes
- Medical Imaging Techniques and Applications
- Neutropenia and Cancer Infections
- Cancer Genomics and Diagnostics
- Chemotherapy-induced cardiotoxicity and mitigation
- Male Breast Health Studies
- Sarcoma Diagnosis and Treatment
Instituto Nacional de Cancerología
2020-2024
Instituto Nacional de Cancerología
2024
Secretaria de Salud
2024
CONSENSO ResumenEl cáncer mamario en estadios tempranos tiene un manejo local (quirúrgico y radioterapia) sistémico específico.Este tipo de incluye el carcinoma ductal in situ los cánceres mama I, IIA, IIB
Breast cancer, in early stages, has specific surgical, radiotherapy, and systemic management.This type of cancer includes ductal carcinoma situ breast cancers stages I, IIA, IIB, IIIA.This tenth update the Mexican Cancer Consensus addressed management stages.The dissemination this consensus contributes to updating homogeneity criteria.This article aims present multidisciplinary cancer.
Abstract INTRODUCTION: Currently, patients with recurrent or metastatic hormone-sensitive breast cancer are treated endocrine therapy (ET) in combination cyclin inhibitors, as it has been shown to improve both overall survival and progression-free survival. However, observed that gBRCA1 gBRCA2 mutations, who receive treatment CDK4/6 have lower OS PFS compared those without mutations. These findings could be due the presence of higher E mRNA levels, which encode protein stimulates CDK2...
Abstract Introduction: In Mexico, hormone positive HER2 negative breast cancer is the most frequent subtype, accounting for 76.6% of cases. For patients undergoing local control management through surgery; adjuvant chemotherapy usually followed depending on different risk factors. order to avoid overtreatment, genomic firms have been approved aiding in a more objective decision. One these Oncotype Recurrence score. The TAILORx and RxPONDER trials provided guidance determining which are...
lncRNAs are noncoding transcripts with tissue and cancer specificity. Particularly, in breast cancer, exhibit subtype-specific expression; they particularly upregulated luminal tumors. However, no gene signature-based laboratory tests have been developed for identification or the differential diagnosis of tumors, since A- B-specific genes identified. B patients clinical interest, most variable response to neoadjuvant treatment; thus, it is necessary develop diagnostic predictive biomarkers...
En los últimos años se han desarrollado diversas intervenciones psicológicas especializadas para disminuir el efecto negativo en la imagen corporal pacientes con cáncer de mama; sin embargo, no cuenta revisiones sistemáticas que permitan valorar su eficacia. Objetivo. Evaluar evidencia y viabilidad las disponibles atender problemas mama. Método. Se realizó una búsqueda literatura campo cuatro principales bases datos mediante sistema PIO. identificaron quince artículos publicados entre 2011...
Abstract Introduction Although temporal trends in breast conserving surgery (BCS) have been described for developed countries like the United States (US), there is a lack of information regarding uptake conservation developing regions world. In countries, implementation might be hindered by availability radiation therapy, training among surgeons, or concerns compliance with follow-up care and surveillance. 2006, Mexican government created Seguro Popular, which provided coverage cancer all...